Search - tctmd.com

Displaying 861 - 880 of 1169

Sort: Relevancy | Date

News Daily News

PREVAIL Publicado: Watchman y Warfarina Ofrecen Protección Similar Frente a los ACV en Pacientes con FA

July 03, 2014

News Daily News

Post-AMI Ischemic Stroke Rates Down, Hemorrhagic Stroke Stable Since 1999

Leah Lawrence

July 03, 2014

News Daily News

Los Índices de ACV Isquémicos Post-AMI Bajan y los de ACV Hemorrágicos se Mantienen Estables desde 1999

Leah Lawrence

July 03, 2014

News Daily News

Long-term Cardiac Rhythm Monitoring More Likely to Detect A-fib After Cryptogenic Stroke

L.A. McKeown

July 03, 2014

News Daily News

La Monitorización a Largo Plazo del Ritmo Cardíaco es Capaz de Detectar FA Post-ACV Criptogénico

L.A. McKeown

July 03, 2014

Presentation

Cryptogenic Stroke and Underlying A-fib

Presenter: Tomasso Sanna

July 01, 2014

Presentation

A-fib in Patients with Cryptogenic Stroke or TIA

Presenter: D.J. Gladstone

July 01, 2014

Presentation

PREVAIL: Prospective Randomized Evaluation of the Watchman LAA Closure Device in Patients with A-fib vs Long-term Warfarin Therapy

Presenter: David R. Holmes Jr.

June 30, 2014

Presentation

National Trends in Stroke after AMI: 1999-2010

Presenter: Y. Wang

June 27, 2014

News Daily News

La Dosis Alta de Edoxaban es Igual de Eficaz que la Warfarina en la Prevención de ACV por FA

Yael L. Maxwell

June 27, 2014

News Daily News

High-Dose Edoxaban as Effective as Warfarin for Stroke Prevention in A-fib

Yael L. Maxwell

June 27, 2014

Presentation

Cerebrovascular Events in 21,105 Patients with A-fib Randomized to Edoxaban Versus Warfarin

Presenter: Robert P. Giugliano

June 24, 2014

Presentation TVT 2014

A Critical Analysis of Present Data on Cerebral Protection after TAVR

Presenter: Axel Linke

June 07, 2014

Presentation TVT 2014

Why Cerebral Protection after TAVR Will Become the Standard of Care

Presenter: Eberhard Grube

June 07, 2014

Presentation TVT 2014

Why Cerebral Protection after TAVR Will be Used Sparingly (if at all) in the Future

Presenter: Ganesh Manoharan

June 07, 2014

Presentation TVT 2014

A Rationale Approach to Adjunct Pharmacotherapy After TAVR (With Stroke in Mind)

Presenter: Susheel Kodali

June 07, 2014

Presentation TVT 2014

Has Stroke Frequency Declined After TAVR?

Presenter: Nicolas M. van Mieghem

June 07, 2014

Presentation TVT 2014

Perspectives from the US CoreValve Trials

Presenter: Jeffrey J. Popma

June 07, 2014

Presentation TVT 2014

Perspectives from the PARTNER Trials

Presenter: Susheel Kodali

June 07, 2014

Presentation TVT 2014

Incidence, Timing, Predictors (New Onset AF, Postdilatation, etc.), and Clinical Impact

Presenter: Samir R. Kapadia

June 07, 2014

Advertisement

PREVAIL Publicado: Watchman y Warfarina Ofrecen Protección Similar Frente a los ACV en Pacientes con FA

Post-AMI Ischemic Stroke Rates Down, Hemorrhagic Stroke Stable Since 1999

Los Índices de ACV Isquémicos Post-AMI Bajan y los de ACV Hemorrágicos se Mantienen Estables desde 1999

Long-term Cardiac Rhythm Monitoring More Likely to Detect A-fib After Cryptogenic Stroke

La Monitorización a Largo Plazo del Ritmo Cardíaco es Capaz de Detectar FA Post-ACV Criptogénico

Cryptogenic Stroke and Underlying A-fib

A-fib in Patients with Cryptogenic Stroke or TIA

PREVAIL: Prospective Randomized Evaluation of the Watchman LAA Closure Device in Patients with A-fib vs Long-term Warfarin Therapy

National Trends in Stroke after AMI: 1999-2010

La Dosis Alta de Edoxaban es Igual de Eficaz que la Warfarina en la Prevención de ACV por FA

High-Dose Edoxaban as Effective as Warfarin for Stroke Prevention in A-fib

Cerebrovascular Events in 21,105 Patients with A-fib Randomized to Edoxaban Versus Warfarin

A Critical Analysis of Present Data on Cerebral Protection after TAVR

Why Cerebral Protection after TAVR Will Become the Standard of Care

Why Cerebral Protection after TAVR Will be Used Sparingly (if at all) in the Future

A Rationale Approach to Adjunct Pharmacotherapy After TAVR (With Stroke in Mind)

Has Stroke Frequency Declined After TAVR?

Perspectives from the US CoreValve Trials

Perspectives from the PARTNER Trials

Incidence, Timing, Predictors (New Onset AF, Postdilatation, etc.), and Clinical Impact

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content